High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults

Autor: GL Phillips, DE Reece, JD Shepherd, MJ Barnett, RA Brown, DA Frei-Lahr, HG Klingemann, BJ Bolwell, JJ Spinelli, RH Herzig

Publikováno v: Blood. 77(7)

Seventy consecutive adult patients with acute myelogenous leukemia (AML), median age 44 years, received high-dose cytarabine (3 g/m2 every 12 hours for 12 doses) followed by daunorubicin (45 mg/m2 daily for three doses) for remission induction. A sin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe68fdd538fdfd0b57e138fc4e56ef97
https://pubmed.ncbi.nlm.nih.gov/2009367

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.

Autor: Eitler J; Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany., Wotschel N; Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany., Miller N; Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany., Boissel L; Nantkwest Inc, Culver City, California, USA., Klingemann HG; Nantkwest Inc, Culver City, California, USA., Wels W; Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.; Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany., Tonn T; Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany t.tonn@blutspende.de.; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jan; Vol. 9 (1).

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Autor: Schönfeld K; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany., Sahm C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany., Zhang C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany., Naundorf S; EUFETS GmbH, Idar-Oberstein, Germany., Brendel C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany., Odendahl M; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden and Transfusion Medicine, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany., Nowakowska P; Institute for Transfusion Medicine and Immunohematology, Goethe University, and German Red Cross Blood Donation Service Baden-Württemberg-Hessen, Frankfurt am Main, Germany., Bönig H; Institute for Transfusion Medicine and Immunohematology, Goethe University, and German Red Cross Blood Donation Service Baden-Württemberg-Hessen, Frankfurt am Main, Germany., Köhl U; Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany., Kloess S; Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany., Köhler S; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany., Holtgreve-Grez H; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany., Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany., Schmidt M; Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany., Schubert R; Pediatric Pulmonology, Allergy and Cystic Fibrosis, University Hospital, Frankfurt am Main, Germany., Kühlcke K; EUFETS GmbH, Idar-Oberstein, Germany., Seifried E; Institute for Transfusion Medicine and Immunohematology, Goethe University, and German Red Cross Blood Donation Service Baden-Württemberg-Hessen, Frankfurt am Main, Germany., Klingemann HG; Conkwest Inc., Cardiff-by-the-Sea, California, USA., Rieger MA; 1] Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany [2] Department of Hematology/Oncology, University Hospital, Frankfurt am Main, Germany [3] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Tonn T; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden and Transfusion Medicine, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany., Grez M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany., Wels WS; 1] Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany [2] German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2015 Feb; Vol. 23 (2), pp. 330-8. Date of Electronic Publication: 2014 Nov 06.

Cellular therapy of cancer with natural killer cells-where do we stand?

Autor: Klingemann HG; Tufts University School of Medicine, Boston, Massachusetts, USA. hans.klingemann@tufts.edu

Publikováno v: Cytotherapy [Cytotherapy] 2013 Oct; Vol. 15 (10), pp. 1185-94. Date of Electronic Publication: 2013 Jun 13.

Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.

Autor: Martin PJ; Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. pmartin@fhcrc.org, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ

Publikováno v: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2009 Jul; Vol. 15 (7), pp. 777-84. Date of Electronic Publication: 2009 May 13.